MAPT and tauopathy: Therefore, in an effort to define the peripheral immune signatures of tauopathy, we carried out single-cell RNA sequencing (scRNA-seq) of peripheral blood mononuclear cells (PBMCs) in individuals with pathogenic MAPT variants—who have (or will develop) FTLD-tau pathology—and cognitively normal, non-carrier controls.